{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:16:13Z","timestamp":1780481773316,"version":"3.54.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["81173008"],"award-info":[{"award-number":["81173008"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China","doi-asserted-by":"crossref","award":["2009CB930300"],"award-info":[{"award-number":["2009CB930300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Project for Excellent Talents of Liaoning Province","award":["LR20110028"],"award-info":[{"award-number":["LR20110028"]}]},{"name":"Key Project for Drug Innovation of China","award":["2010ZX09401-304"],"award-info":[{"award-number":["2010ZX09401-304"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.ijpharm.2012.02.022","type":"journal-article","created":{"date-parts":[[2012,2,19]],"date-time":"2012-02-19T11:02:56Z","timestamp":1329649376000},"page":"358-364","source":"Crossref","is-referenced-by-count":23,"title":["Relationship between dissolution and bioavailability for nimodipine colloidal dispersions: The critical size in improving bioavailability"],"prefix":"10.1016","volume":"427","author":[{"given":"Qiang","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longfa","family":"Kou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meina","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonggui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2012.02.022_bib0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0010","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1172\/JCI44778","article-title":"A noninhibitory mutant of the caveolin-1 scaffolding domain enhances eNOS-derived NO synthesis and vasodilation in mice","volume":"121","author":"Bernatchez","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0015","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/03639040500216212","article-title":"Physical\u2013chemical characterization and polymorphism determination of two nimodipine samples deriving from distinct laboratories","volume":"31","author":"Cardoso","year":"2005","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0020","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0378-5173(86)90050-5","article-title":"Effect of lipid class and lipid vehicle volume on the intestinal lymphatic transport of DDT","volume":"33","author":"Charman","year":"1986","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0025","unstructured":"Fu, Q., Sun, J., Ai, X., Kou, L., Gong, C., He, Z. What accounts for unfavoured in vitro in vivo correlation of nimodipine nanocrystals and solid dispersions: molecular form versus crystal form, under review."},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0030","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1080\/03639040701741810","article-title":"Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement","volume":"33","author":"Gao","year":"2007","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0378-5173(94)00284-C","article-title":"Polymorphism in binary mixtures, as exemplified by nimodipine","volume":"118","author":"Grunenberg","year":"1995","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0040","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ejps.2003.11.009","article-title":"Development of a dissolution medium for nimodipine tablets based on bioavailability evaluation","volume":"21","author":"He","year":"2004","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0045","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jconrel.2005.11.013","article-title":"Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs","volume":"111","author":"Jinno","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0050","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1248\/cpb.26.2603","article-title":"Dissolution of slightly soluble drugs. V. Effect of particle size on gastrointestinal drug absorption and its relation to solubility","volume":"26","author":"Kaneniwa","year":"1978","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2011.08.032","article-title":"Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications","volume":"420","author":"Kawabata","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0060","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejps.2008.07.003","article-title":"Intestinal lymphatic transport of halofantrine in rats assessed using a chylomicron flow blocking approach: the influence of polysorbate 60 and 80","volume":"35","author":"Lind","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0378-5173(95)00122-Y","article-title":"Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs","volume":"125","author":"Liversidge","year":"1995","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0070","doi-asserted-by":"crossref","first-page":"8951","DOI":"10.1021\/la061122t","article-title":"Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization","volume":"22","author":"Matteucci","year":"2006","journal-title":"Langmuir"},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0075","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3109\/03639045.2010.538061","article-title":"Strategies to improve dissolution and oral absorption of glimepiride tablets: solid dispersion versus micronization techniques","volume":"37","author":"Ning","year":"2011","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0080","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1211\/0022357023691","article-title":"Nanosuspensions: a promising drug delivery strategy","volume":"56","author":"Patravale","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijpharm.2004.09.007","article-title":"Enhancement of dissolution rate of poorly-soluble active ingredients by supercritical fluid processes. Part I: Micronization of neat particles","volume":"288","author":"Perrut","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0090","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2217\/nnm.09.110","article-title":"Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery","volume":"5","author":"Roger","year":"2010","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0095","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2010.01.036","article-title":"Endocytosis of nanomedicines","volume":"145","author":"Sahay","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ijpharm.2010.07.044","article-title":"Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives","volume":"399","author":"Shegokar","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0105","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3109\/03639040903025855","article-title":"Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development","volume":"35","author":"Sigfridsson","year":"2009","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0110","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3109\/03639045.2010.504209","article-title":"A formulation comparison between micro- and nanosuspensions: the importance of particle size for absorption of a model compound, following repeated oral administration to rats during early development","volume":"37","author":"Sigfridsson","year":"2011","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0115","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1002\/jps.22587","article-title":"Nanonization of itraconazole by high pressure homogenization: stabilizer optimization and effect of particle size on oral absorption","volume":"100","author":"Sun","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0120","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijpharm.2008.07.023","article-title":"Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products","volume":"364","author":"Van Eerdenbrugh","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11095-004-9004-4","article-title":"Predicting drug disposition via application of BCS: transport\/absorption\/elimination interplay and development of a biopharmaceutics drug disposition classification system","volume":"22","author":"Wu","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0130","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijpharm.2004.08.001","article-title":"The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a beagle dog model predicts improved bioavailability and diminished food effect on absorption in human","volume":"285","author":"Wu","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2012.02.022_bib0135","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s11095-010-0200-0","article-title":"Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats","volume":"27","author":"Xia","year":"2010","journal-title":"Pharm. Res."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037851731200155X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037851731200155X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T02:13:49Z","timestamp":1588817629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037851731200155X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S037851731200155X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2012.02.022","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}